Table 4.
Selected Subsequent Anticancer Therapy
| Therapy | No. (%) of Patients |
|
|---|---|---|
| Trabectedin (n = 345) | Dacarbazine (n = 173) | |
| Total with subsequent anticancer chemotherapy | 162 (47) | 97 (56) |
| Pazopanib | 63 (18) | 48 (28) |
| Dacarbazine | 60 (17) | 11 (6) |
| Radiation | 35 (10) | 25 (15) |
| Gemcitabine | 30 (9) | 25 (15) |
| Surgery | 23 (7) | 17 (10) |
| Docetaxel | 19 (6) | 21 (12) |
| Ifosfamide | 7 (2) | 10 (6) |
| Doxorubicin | 9 (3) | 5 (3) |
| Eribulin | 9 (3) | 1 (1) |
| Trabectedin | 1 (< 1) | 4 (2) |
NOTE. Subsequent anticancer therapies that were used for at least 5% of patients in either treatment group were included. In addition, doxorubicin, eribulin, and trabectedin were also included on the basis of their previously demonstrated activities.